Literature DB >> 27957523

Recurrent acral angioosteoma cutis in a pregnant patient.

Allison L Wang1, Travis Vandergriff1, Divya Srivastava1, Rajiv I Nijhawan1.   

Abstract

Entities:  

Keywords:  AAOC, acral angioosteoma cutis; BMP, bone morphogenic protein; PG, pyogenic granuloma; VEGF, vascular endothelial growth factor; acral angioosteoma cutis; bone morphogenic proteins; metaplastic calcification; pregnancy; pyogenic granuloma; vascular endothelial growth factor

Year:  2016        PMID: 27957523      PMCID: PMC5143410          DOI: 10.1016/j.jdcr.2016.09.012

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.

Introduction

Googe et al in 2006 first described 11 cases of acral angioosteoma cutis (AAOC), characterized by benign vascular and osseous lesions on acral skin. Since then, there have been only 3 additional cases reported.2, 3, 4 This friable erythematous exophytic papule has clinical resemblance to pyogenic granuloma (PG) but has distinct histologic features. Therefore, it is crucial for dermatologists to be aware of this condition, as it is rare and likely often misdiagnosed. To our knowledge, this case is the first report of AAOC in pregnancy.

Case report

A 12-week-pregnant 35-year-old woman presented with an approximately 4-week history of a growing, tender papule under her right great toenail. She initially noticed nail discoloration; then she reported progressively worsening discomfort with lifting of her nail plate. She denied any other medical problems, denied any medications other than prenatal vitamins, and reported no complications with her pregnancy. Four weeks later, once she was well into the second trimester of her pregnancy, a shave removal with electrodessication of the base was performed after reflecting the nail plate proximally to expose the lesion. The patient subsequently returned 8 weeks postprocedure reporting evidence of recurrence that began approximately 2 weeks prior. On evaluation of this recurrence, a 0.8- × 0.9-cm friable erythematous papule was noted under the onycholytic distal right great toenail and extended distal to the onychodermal band (Fig 1). Using a nail splitter, the nail plate was vertically cut and reflected proximally to completely visualize the lesion. A deeper shave removal was performed with aggressive electrodessication of the base to minimize risk of recurrence. The nail plate was subsequently reflected back into place.
Fig 1

Right great toe with subungual friable red papule extending distal to the onychodermal band.

Histopathologic examination found an inflammatory crust covering an ulceration that consisted of a dense proliferation of capillaries and endothelial cells in the dermis (Fig 2). The capillaries were not arranged in lobules and rather were dispersed among spicules of mineralized bone. The spicules of bone contained osteocytes and were lined by benign-appearing osteoblasts (Fig 3).
Fig 2

Histopathology of shave removal specimen shows dermal proliferation of bony spicules and dispersed capillaries. (Hematoxylin-eosin stain; original magnification: ×20.)

Fig 3

Mineralized bony spicules with benign-appearing osteocytes and osteoblasts among dilated capillaries. (Hematoxylin-eosin stain; original magnification: ×200.)

Discussion

Clinically, AAOC appears as a friable erythematous exophytic papule on digits, palms, or soles and can develop at any age with slight female predominance. It closely resembles other benign lesions such as PG. In addition to clinical similarity, AAOC could be misdiagnosed as PG with ossification because of the vascular and bony growth on histology. Of 4 reports of PG with ossification, only one commented on the lobular vascularity.5, 6, 7, 8 Kim et al describes PG with ossification as lobular proliferation of capillaries with spicules of spongy bone with osteocytelike and osteoblastlike cells. The distinguishing feature of AAOC is that the capillary formation is not lobular as seen in PG but rather a diffuse pattern. Histologically in AAOC the diffuse capillary formations have spicules of woven bones dispersed. No lamellar bone or cartilage is seen. AAOC can also mimic other benign growths. Subungual exostosis usually presents as a growth under the nail, causing onycholysis. However, subungual exostosis has a fibrous cap and lacks capillary proliferation. Peripheral ossifying fibroma resembles PG clinically but occurs exclusively in the gingiva. Although peripheral ossifying fibroma exhibits features of vascular proliferation and ossification, it mostly contains fibroblasts and stroma. The pathogenesis of AAOC remains unclear. Burgdorf and Nasemann proposed 2 theories of cutaneous ossification. One notion is that primitive mesenchymal cells differentiate into normal osteoblasts in the wrong location. The other theory is that undifferentiated mesenchymal cells undergo metaplastic differentiation in the setting of inflammation or hypoxia. In previous case reports, the investigators believed that the vascular proliferation in both AAOC and PG were induced by vascular endothelial growth factor (VEGF).2, 3, 4 Endothelial cells produce signals such as bone morphogenic protein (BMP) to induce metaplastic differentiation and ectopic bone formation. Osteoblasts are also responsible for production of VEGF. The combination of VEGF and hypoxia induce BMP expression. Together, VEGF and BMP are the most likely factors that induce vascular proliferation and bone formation in AAOC. Because AAOC might be misdiagnosed as PG or other benign cutaneous neoplasm, it may not be rare but rather underreported. With the possible driving factors of VEGF and BMP, this lesion is benign and can recur after excision. Dermatologists should be aware of the distinguishing features of scattered bone formation and diffuse capillary proliferation of AAOC rather than the lobular aggregates in PG. Surgical removal of AAOC is the treatment of choice. Thirteen of 14 cases had no documented recurrence. In our patient, the lesion did not recur after the second surgical removal after 6 months of observation.
  9 in total

1.  Cutaneous ossification. Report of 120 cases and review of the literature.

Authors:  S I ROTH; R E STOWELL
Journal:  Arch Pathol       Date:  1963-07

2.  Acral angioosteoma cutis.

Authors:  Eun-Ju Lee; Jong-Ho Lee; Min-Kyung Shin; Sung-Won Lee; Choong-Rim Haw
Journal:  Ann Dermatol       Date:  2011-09-30       Impact factor: 1.444

3.  Acral Angioosteoma Cutis on the Great Toe Mimicking Pyogenic Granuloma.

Authors:  Chae Young Won; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

4.  Acral angioosteoma cutis.

Authors:  Hee Jin Song; Won Kyu Hong; Sung Hyub Han; Ji Won Byun; Hyeon Sook Lee; Gwang Seong Choi; Jeong Hyun Shin
Journal:  Am J Dermatopathol       Date:  2010-07       Impact factor: 1.533

5.  Bone formation in a cutaneous pyogenic granuloma.

Authors:  R A Fulton; G D Smith; J Thomson
Journal:  Br J Dermatol       Date:  1980-03       Impact factor: 9.302

6.  Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts.

Authors:  O Kozawa; H Matsuno; T Uematsu
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

7.  Hypoxia and VEGF up-regulate BMP-2 mRNA and protein expression in microvascular endothelial cells: implications for fracture healing.

Authors:  Pierre J Bouletreau; Stephen M Warren; Jason A Spector; Ziv M Peled; Rene P Gerrets; Joshua A Greenwald; Michael T Longaker
Journal:  Plast Reconstr Surg       Date:  2002-06       Impact factor: 4.730

8.  Metaplastic ossification in a cutaneous pyogenic granuloma: a case report.

Authors:  Eun Sung Kim; Kyoung Jin Kim; Sung Eun Chang; Mi Woo Lee; Jee Ho Choi; Kee Chan Moon; Jai Kyoung Koh
Journal:  J Dermatol       Date:  2004-04       Impact factor: 4.005

9.  Cutaneous osteomas: a clinical and histopathologic review.

Authors:  W Burgdorf; T Nasemann
Journal:  Arch Dermatol Res       Date:  1977-12-12       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.